IMR Press / EJGO / Volume 22 / Issue 2 / pii/2001128

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium

Show Less
1 Zerifin Affiliated with Sackler School of Medicine, Tel-Aviv University, Tel-Avzv, Israel
2 Department of Pathology, Assaf Harofeh Medical Center, Zerifin Affiliated with Sackler School of Medicine, Tel-Aviv University, Tel-Avzv, Israel
3 Science Based Industrial Park, Nes Ziona, Israel
Eur. J. Gynaecol. Oncol. 2001, 22(2), 122–126;
Published: 10 April 2001

Objective: The aim of this study was to determine whether immunohistochemical analysis of molecular parameters can provide an alternative method for classification of endometrial cancer cases according to their aggressiveness. Methods: Sixty-four cases of endometrial carcinoma were assigned to three groups: group I - 28 cases of endometrioid well and moderately differentiated (G, -G,) carcinoma; group II - 14 cases of endometrioid poorly differentiated (G3) carcinoma; group III - 22 cases of serous papillary endometrial cancer. lmmunohistochemistry was used to determine the existence of estrogen receptors (ER), progesterone receptors (PR), and the expression of bcl-2, p53, HER-2/neu and Ki-67. Results: There was a significant difference in the immunohistochemical profile of the studied molecular parameters comparing the three study groups. The endometrioid G, -G, cases (group 1) were characterized by increased immunoreactivity for ER and PR (85.7% and 78.6%, respectively), increased immunoreactivity for bcl-2 (42.8%) and low expression of p53 (14.3%) and HER-2/neu (14.3%). In contrast to group I cases, the serous papillary endometrial cancer cases (group III) were characterized by immunone­gativity for ER, PR and bcl-2 and high immunoreactivity for p53 (81.8%) and HER-2/neu (45.4%). The endometrioid G3 cases (group II) demonstrated an intermediate immunoprofile, characterized by immunonegativity for ER, PR and HER-2/neu, low immu­noreactivity for bcl-2 (7.1 %) and high expression of p53 (57.1 %). The expression of Ki-67 did not differ significantly comparing the different cases of endometrial cancer.Conclusion: This study provides evidence that the immunohistochemical analysis of endometrial carcinoma differentiates between different grades and histological types, thus being useful in the distinction of high risk cases.

Endometrioid carcinoma of endometrium
Serous papillary carcinoma of endometrium
Molecular markers
Back to top